Answers are grounded in this paper and cite their sources.
OBJECTIVES/BACKGROUND: High-frequency episodic migraine (HFEM) represents a clinically important subset of episodic migraine characterized by increased disease burden, greater functional impairment, and elevated risk of migraine chronification. Atogepant is an oral calcitonin gene-related peptide receptor antagonist approved for the preventive treatment of migraine. The objective of this analysis was to evaluate the efficacy and safety of atogepant 60 mg once daily for the preventive treatment of migraine in adults with HFEM, including in those with inadequate responses to ≥2 clasess of conventional oral non-migraine-specific preventive treatements. METHODS: This post hoc, exploratory subgroup analysis examined participants from two 12-week, phase 3, randomized, double-blind, placebo-controlled trials (ADVANCE and ELEVATE). Two subgroups were examined: the ADVANCE HFEM subgroup, which included participants from ADVANCE with 8-14 monthly migraine days (MMDs) at baseline, and the HFEM TF2+ subgroup, which comprised of pooled HFEM participants from ADVANCE and ELEVATE who had an inadequate response to ≥2 classes of conventional oral non-migraine-specific preventive migraine treatments. Efficacy outcomes included the change from baseline in mean MMDs, mean monthly acute medication use days, and proportion of participants achieving a ≥50%, ≥75%, or 100% reduction in mean MMDs across the 12-week double-blind treatment period. Functional outcomes included change from baseline in Migraine-Specific Quality of Life Questionnaire version 2.1 Role Function-Restrictive domain score, and Headache Impact Test-6 total score at week 12. Safety was assessed separately for each subgroup. RESULTS: The ADVANCE HFEM subgroup included 203 participants from the modified intent-to-treat population and the pooled HFEM TF2+ subgroup included 269 participants. Atogepant 60 mg once daily was associated with a greater reduction from baseline in mean MMDs compared with placebo in both the ADVANCE HFEM (least squares mean difference [LSMD] = -1.93 [95% confidence interval [CI] = -2.93 to -0.94]; nominal p < 0.001) and the pooled HFEM TF2+ subgroup (LSMD = -2.65 [95% CI = -3.60 to -1.71]; nominal p < 0.001). Reductions in mean monthly acute medication use days were similarly greater with atogepant (ADVANCE HFEM LSMD = -1.76 [95% CI = -2.58 to -0.94]; HFEM TF2+ LSMD = -2.80 [95% CI = -3.61 to -2.00]; both nominal p < 0.001). Improvements in the Migraine-Specific Quality of Life Questionnaire version 2.1 Role Function-Restrictive domain (ADVANCE HFEM LSMD = 9.89 [95% CI = 3.42-16.35]; HFEM TF2+ LSMD = 16.94 [95% CI = 11.93-21.96]) and Headache Impact Test-6 total score (ADVANCE HFEM LSMD = -3.35 [95% CI = -5.46 to -1.23]; HFEM TF2+ LSMD = -5.61 [95% CI = -7.47 to -3.75]) exceeded between-group minimally important differences (all nominal p ≤ 0.003). Safety outcomes were consistent with the full trial populations and the known safety profile of atogepant. CONCLUSION: In this post hoc subgroup analysis, atogepant 60 mg once daily showed greater improvements in efficacy and functional outcomes compared with placebo for the preventive treatment of HFEM, including in those with an inadequate response to ≥2 classes of conventional oral non-migraine-specific preventive treatments. These findings suggest atogepant represents an effective and well-tolerated option for the preventive treatment of migraine in adults with HFEM, a population at elevated risk for chronification (NCT03777059; NCT04740827).
No takes yet. Share an insight, caveat, or question.
Ashina et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: